| Literature DB >> 25535908 |
Qiang Liu1,2, Ran Zou1, Rouxi Zhou3, Chaofan Gong3, Zhifei Wang2, Tao Cai2, Chaochao Tan2, Jiasheng Fang1.
Abstract
The critical role of microRNAs in cancer development has been extensively described. miRNAs are both specific markers and putative therapy targets. miR-155 has been identified to be an oncomiRNA and is highly expressed in several solid cancers, including glioblastoma. In this study, we found that miR-155 is a good potential therapy target. Knockdown of miR-155 sensitizes glioma cells to the chemotherapy of temozolomide (TMZ) by targeting the p38 isoforms mitogen-activated protein kinase 13 [MAPK13, also known as p38 MAPKδ or stress-activated protein kinase 4 (SAPK4)] and MAPK14 (also known as p38 MAPKα). As tumor suppressor genes, MAPK13 and MAPK14 play important roles in lowering the accumulation of reactive oxygen species (ROS), inducing cell apoptosis, and slowing the progression of cancer. Knockdown of miR-155 enhanced the anticancer effect of TMZ on glioma by targeting the MAPK13 and MAPK14-mediated oxidative stress and apoptosis, but did not affect the secretion of MMP2 and MMP9.Entities:
Keywords: CHEMOSENSITIVITY; GLIOBLASTOMA; MAPK; REACTIVE OXYGEN SPECIES; TEMOZOLOMIDE; microRNA
Mesh:
Substances:
Year: 2015 PMID: 25535908 DOI: 10.1002/jcb.25073
Source DB: PubMed Journal: J Cell Biochem ISSN: 0730-2312 Impact factor: 4.429